

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/650,579 08/28/2003		08/28/2003	Donald R. Merritt	P-9694.01	8240
27581	7590	09/03/2004		EXAMINER	
MEDTRON	NIC, INC	•	LAYNO, CARL HERNANDZ		
710 MEDTR	ONIC PA	RKWAY NE			
MS-LC340				ART UNIT	PAPER NUMBER
MINNEAPO	LIS, MN	55432-5604	3762		

DATE MAILED: 09/03/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		•					
	Application No.	Applicant(s)					
	10/650,579	MERRITT ET AL.					
Office Action Summary	Examiner Cul H. Layro Carl H. Layro G/2/04	Art Unit					
		3762					
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with the	correspondence address					
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory perio - Failure to reply within the set or extended period for reply will, by statue Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	I. 1.136(a). In no event, however, may a reply be to the statutory minimum of thirty (30) daily will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDON	imely filed ays will be considered timely. In the mailing date of this communication. IED (35 U.S.C. § 133).					
Status	•						
1) Responsive to communication(s) filed on 28	August 2003.						
	<u> </u>						
,	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) ☐ Claim(s) 1-4 is/are pending in the application 4a) Of the above claim(s) is/are withdr 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-4 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and	awn from consideration.						
Application Papers							
9) The specification is objected to by the Examin	ner.						
•	☐ The specification is objected to by the Examiner. ☐ The drawing(s) filed on <u>28 August 2003</u> is/are: a)☐ accepted or b)☑ objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure	nts have been received. nts have been received in Applica iority documents have been receive eau (PCT Rule 17.2(a)).	ition No ved in this National Stage					
* See the attached detailed Office action for a li	st of the certified copies not receive	/ed.					
Attachment(s)	_						
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summar Paper No(s)/Mail I						
 Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date 	_	Patent Application (PTO-152)					

DETAILED ACTION

Priority

1. Acknowledgment is made of applicant's claim for priority as a Continuation of U.S. Application Serial No. 09/970,374, now U.S. Patent No. 6,671,552.

Drawings

2. Applicant's drawings are objected to by the Draftsperson. See attached PTO-948.

Claim Objections

3. Claims 2 and 3 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

Specifically, claims 2 and 3 fail to limit parent claim 1, since they currently depend from a non-existent "claim 25". To overcome this objection, the Examiner recommends changing the dependency of these claims to depend from claim 1.

Double Patenting

4. Claims 1 and 4 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 28, 29, and 30 of U.S. Patent No. 6,671,552, respectively. Although the conflicting claims are not identical, they are not patentably distinct

Page 3

from each other because the method steps recited in applicant's claim 1 reads verbatim on the first part of claims 28 and 29 of U.S Patent No. 6,671,552, and because the elements of applicant's claim 4 read word-for-word upon the details recited in the first half of claim 30 of U.S. Patent No. 6,671,552.

Claim Rejections - 35 USC § 112

- 5. The following is a quotation of the second paragraph of 35 U.S.C. 112:
 - The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 6. Claims 2 and 3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, there is no antecedent basis for a "step c)" (claim 2) and a "step b)" (claim 3) in base claim 1. To overcome this rejection, the Examiner recommends either altering claim 1 to include step reference letters "a)", "b)", and "c)", or replacing the references to "step c)" and "step b)" in claims 2 and 3, respectively, with proper references to their corresponding method steps.

Claim Rejections - 35 USC § 102

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Application/Control Number: 10/650,579

Art Unit: 3762

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

8. Claims 1 and 4 are rejected under 35 U.S.C. 102(e) as being anticipated by Snell et al '579 or Busacker et al '448.

The Snell et al '579 patent describes a battery monitoring apparatus 110 (Fig. 1) for realistically estimating the remaining life of a battery 70 in an implantable cardiac stimulating device 10. The device measures battery voltage E_{BAT} to calculate battery current drain $I_{CONSUMED}$ using Ohm's law: $I_{CONSUMED} = E_{BAT}/R_{OHMIC CIRCUITS}$ (col.9, line 20). This current drain 350 (Fig.5), along with the measured battery voltage 394, are used in determining an estimated remaining battery life (i.e. the time remaining until the battery's recommended replacement time (RRT)), which is calculated then displayed to the user 430 (Fig.5).

The Busacker et al '448 patent describes an implantable medical device 10 (Fig. 1 and 2) having the ability to measure battery voltage and current drain (see Fig. 4b and col. 19, line 43 thru col. 20, line 48), and based upon these measures, to calculate a remaining effective battery lifetime (DT) between an elective replacement indicator time (ERI) and a time at which erratic pacing takes place due to battery exhaustion. This remaining battery time (DT) is calculated by the formula DT=DQ/I. See col. 19, line 65 thru col. 20, line 11.

Application/Control Number: 10/650,579

Art Unit: 3762

Conclusion

Page 5

9. The prior art made of record and not relied upon is considered pertinent to applicant's

disclosure.

The Stessman '355 patent describes an implantable cardiac stimulating device having

pertinent battery current measurement capabilities. Unlike applicant's device, however, the

reference does not appear to calculate or estimate remaining battery life...

Any inquiry concerning this communication or earlier communications from the 10.

examiner should be directed to Carl H. Layno whose telephone number is (703) 308-3694. The

examiner can normally be reached on Monday thru Thursday from 9 AM to 6 PM and every

other Friday between 9AM and 5PM. A voice mail or E-mail message (carl layno@uspto.gov)

may be left if desired.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Angela Sykes, can be reached on (703) 308-5181. All faxed correspondence should

be sent to the Office's new official FAX number (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to Legal Instruments Examiner (LIE) Brenda Webb whose telephone number

is (703) 305-7520.

CARL LAYNO

PRIMARY EXAMINER

Carl N. Layro

9/1/2004

CHL